Close this search box.

Broughton expands into North America for next phase of growth

Home » Broughton expands into North America for next phase of growth

Global Contract Research Organisation Broughton is expanding into North America due to a growing customer base in the region.

Delivering products across the pharmaceutical, nicotine and cannabinoid sectors, Broughton Group is establishing a US Subsidiary to build its presence in North America.

Dr Tony Jones will be joining Broughton as managing consultant to lead the US team, and the company has expanded its toxicology team and experimental toxicology capabilities with the additions of Libby Clarke and Dr Carol Beevers.

Broughton CEO, Chris Allen, CEO, commented: “Since 2006, our focus has always been to help our clients succeed. With a passion for enhancing societal health and wellbeing, the establishment of a North American subsidiary is a natural next step to enable us to better partner with our customers in the region.

“The ongoing expansion of our team reflects our continued commitment and ambition to become the most trusted integrated services provider in the world.”

Jones will be bringing his experience in the field of toxicology, risk assessment and project delivery for clients operating in the pharmaceutical, nicotine and cannabinoid industries.

Read more: Structure change to drive the growth of Broughton

“I am delighted to be spearheading this exciting next stage of the development of Broughton in the US market,” said Jones.

“I’m looking forward to introducing the full lifecycle development services offered by the Broughton team to US clients across pharmaceuticals, nicotine and cannabinoids to help the company support their clients to accelerate innovation to market and improve health outcomes.”

Broughton expands into North America for next phase of growth
Dr Tony Jones

The Broughton team has been further expanded with the addition of Oliver Knight-West, In recognition of the growing importance of behavioral science in regulatory submissions. Knight-West has conducted multiple behavioral and clinical studies into next-generation nicotine products (NGPs) and pharmaceuticals for dossier submission to the FDA, MHRA and EMA regulatory bodies. He has also published scientific papers in several publications.

Malcolm Saxton has also joined the company’s chemistry consultancy team, where he will help ensure that Broughton remains at the forefront of the industry in terms of novel method development aligned with evolving market and regulatory needs.

[activecampaign form=31]

Related Posts

Related Posts


Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you


Browse by Tags




© 2023 Prohibition Holdings Ltd. All Rights Reserved.


Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?